VISIT NUTRACEUTICALS WORLD
AT BOOTH #2227

Euromed Partners with Biotherapeutics to Launch Abscisic Acid

10.03.17

ABA Life fig fruit extract shown to be beneficial in glycemic control and carbohydrate metabolism.

Euromed SA, a manufacturer of therapeutic botanical extracts, has received an exclusive license agreement with BioTherapeutics Inc. for patented technology for absiscic acid (ABA). 
 
The patents licensed by Euromed are titled: “Method of using abscisic acid to treat diseases and disorders” (Patent numbers 7,741,1367 and 8,367,727, and the Inventors are Josep Bassaganya-Riera, Raquel Hontecillas, and Amir Guri). The invention relates to biologically active compounds (ABA) that treat and prevent insulin resistance and impaired glucose tolerance. The patents provide protection for structure-function claims related to ABA and maintenance of healthy blood sugar levels and similar statements. 
 
By partnering with BioTherapeutics, “Euromed continues to seek ingredient innovation that will address broad-based health concerns for consumers globally,” commented Javier Roig CEO of Euromed S.A. “ABA Life, our tradename for this ingredient can provide a safe and effective dietary supplement to aid in correcting impaired carbohydrate metabolism.” 
 
ABA Life is a proprietary all-natural line of botanical extracts that contain abscisic acid. The first product to be introduced is an extract from fig fruit, Ficus carica L. Figs, a long-standing foodstuff of Mediterranean populations grow naturally throughout Spain and have one of the highest concentrations of abscisic acid found in nature. About 92% of Americans do not consume adequate fruits and vegetables and may be deficient in ABA. ABA Life delivers the scientifically proven health benefits of ABA while avoiding additional calories associated with eating figs.   
 
“We are looking forward to partner with Euromed to accelerate the development of new ABA-containing nutritional products for glycemic control,” said Josep Bassaganya-Riera, president and CEO of BioTherapeutics. “We anticipate that the first product containing ABAlife will be a functional health water to be launched in the U.S. market under the Pervida brand. The Pervida brand is currently commercializing Pervida Immune for gut and immune health, and in 2018 it will launch Pervida Control, the first ABA-containing beverage for glycemic control.”
 
The average American consumes 19.5 teaspoons of sugar every day. That quantity adds up to 66 pounds of added sugar consumed per person every year. Sugar increases the level of glucose in the blood and causes the pancreas to release insulin. Higher insulin leads to more storage of dietary calories as fat. ABA Life™ assists insulin release and lowers blood glucose.
 
According to Centers For Disease Control, another 86 million adults – more than one in three U.S. adults – have prediabetes, where their blood sugar levels are higher than normal but not high enough to be classified as type 2 diabetes.  
 
Without weight loss and moderate physical activity, 15 to 30% of people with prediabetes will develop type 2 diabetes within five years.  
 
According to the latest U.S. dietary survey, about 92% of the population might have a deficient intake of ABA due to their deficient intake of fruits and vegetables that is under the recommended 4.5 servings per day. High glucose concentrations cause the β-pancreatic cells to release ABA which in turn simulates insulin release, suggesting a beneficial effect of ABA in glycemic control. ABA consumed as a dietary supplement will be an aid in improving glucose tolerance in healthy individuals and those seeking health enhancement.